Recursion Pharmaceuticals (NASDAQ:RXRX) is a biotechnology company that applies advanced machine learning, automation and high‐throughput biology to accelerate the discovery and development of new medicines. Headquartered in Salt Lake City, Utah, the company has built a proprietary platform that integrates imaging-based cellular assays with artificial intelligence to analyze disease models at an unprecedented scale. By combining experimental biology and deep data, Recursion aims to identify novel therapeutic opportunities faster than traditional approaches, focusing on areas of high unmet medical need.
Founded in 2013 by a team of researchers and technologists, Recursion has expanded its operations to include multiple laboratory facilities and computational centers in the United States and select international sites. Its internal pipeline spans a diverse range of therapeutic areas, including rare genetic disorders, immunology and oncology. The company leverages its extensive compound libraries and phenotype-driven screens to prioritize and advance lead candidates into preclinical development, with the goal of delivering first‐in‐class or best‐in‐class therapies.
Recursion maintains strategic collaborations and partnerships with leading pharmaceutical and biotechnology firms to co-develop novel drug candidates. These alliances provide access to additional resources, proprietary targets and global development expertise, enabling Recursion to augment its internal capabilities and accelerate timelines. The company’s platform has been applied to both small-molecule and biologics discovery projects, demonstrating its flexibility across multiple molecular modalities.
Leadership at Recursion includes Chief Executive Officer Blake W. Borgeson and Chief Scientific Officer Chris Gibson, among others with deep experience in technology, data science and drug development. The management team emphasizes a data-centric culture and continuous innovation, investing heavily in research infrastructure and cross-functional talent. Through its unique integration of biology and computation, Recursion aims to reshape the pharmaceutical R&D paradigm and bring transformative treatments to patients worldwide.
